Certara, Inc.
CERT
Positions held
Your positionsCERT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Certara operates in the growing health information services industry, which is increasingly vital for drug development and regulatory compliance.
- The company has a target mean price of $8.62, indicating potential upside from its current valuation.
- Certara's gross margin improved to 62.3% in the latest quarter, up from 61.1% in the prior quarter.
- Despite its growth potential, Certara has a negative profit margin of -16.2%, indicating ongoing profitability challenges.
- The company reported a revenue decline of 13% compared to the previous quarter, from $107M to $93M.
- Certara's operating margin remains negative at -0.2%, reflecting ongoing operational difficulties.
Fundamentals
| Market cap | $1.32B | Enterprise value | $1.44B | Trailing P/E | — | Forward P/E | 22.17 |
| PEG | — | Price / book | 1.36 | Beta | 1.43 | Dividend yield | 0.00% |
| Revenue growth | 1.0% | Earnings growth | — | Gross margin | 61.6% | Operating margin | -0.2% |
| Profit margin | -16.2% | ROE | -2.2% | ROA | 0.8% | Debt / equity | 0.31 |
| Current ratio | 2.55 | Free cash flow | $62.58M | Analyst recommendation | buy | Mean target | $8.71 |
| 52w high | $13.11 | 52w low | $4.45 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $93.3M | $107M | $104M | $105M | $92.4M | — |
| Op margin | -0.2% | -4.0% | 0.8% | 2.9% | 8.3% | — |
| Net income | -$55.3M | -$8.8M | -$5.9M | $1.5M | -$2.0M | — |
| Gross margin | 62.3% | 61.1% | 62.2% | 62.0% | 62.9% | — |
| Gross profit | $58.1M | $65.3M | $64.5M | $64.9M | $58.1M | — |
| Operating income | -$0.2M | -$4.3M | $0.8M | $3.0M | $7.7M | — |
- Revenue -13% vs prior quarter ($93M vs $107M).
- Gross margin 62.3% (was 61.1% prior quarter).
- Operating margin expanded to -0.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $419M | $385M | $354M | $336M | — |
| Op margin | 5.0% | -0.4% | 1.8% | 9.7% | — |
| Net income | -$1.6M | -$12.1M | -$55.4M | $14.7M | — |
| Gross margin | 61.5% | 59.9% | 60.2% | 60.5% | — |
| Gross profit | $258M | $231M | $213M | $203M | — |
| Operating income | $21.0M | -$1.7M | $6.2M | $32.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · What Could Go Wrong With Recursion Pharmaceuticals Stock?
2026-09-30 · UBS Downgrades Certara to Neutral From Buy, $10 Price Target
2026-09-14 · Certara (CERT) Slashes Jobs While Doubling Down On Software Growth
2026-09-03 · Cerrado Gold Closes $10 Million Strategic Private Placement with Eric Sprott
2026-08-31 · Cerrado Gold Announces $10 Million Strategic Private Placement with Eric Sprott
2026-08-24 · Cerrado Gold Appoints Chris MacInnis as Vice President, Geology
2026-08-07 · The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why
2026-08-05 · Certara (CERT) Q2 2026 Earnings Call Transcript
2026-08-05 · Certara, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns